Finding Metabolomic Signatures in Pregnancy that Predict Breast Cancer: 60 Year Prospective Study in the Child Health and Development Studies Pregnancy Cohort
Abstract
In this project, we have proposed to identify predictive gestational biomarkers which could lead to new approaches to prevent breast cancer. For this, we are applying ultrahigh-resolution mass spectrometry-based high-resolution metabolomics (HRM) to analyze 2nd and 3rd trimester archival serum samples of women in the Child Health and Development Studies (CHDS) pregnancy cohort who subsequently developed breast cancer or did not develop breast cancer. HRM data of these two groups will be compared to identify environmental chemicals and metabolites, and biochemical metabolic networks in pregnancy which are linked to subsequent breast cancer occurrence. There were minor delays caused by staff and offices transitioning to remote work due to the COVID-19 pandemic in CHDS (Site 1). CHDS still accomplished all major tasks specified in the first year (obtaining all human subjects approvals, sample selection, preparation and order of archived pregnancy serum) and will deliver these samples to Emory (Site 2) in this month. Emory has not yet received samples. While waiting for samples, we have expanded our list of chemicals with confirmed identity which we can measure and have proceeded with methods to optimize workflow. A key workflow change has been to establish cloud computing through Emory-sponsored Amazon Web Services (AWS) to obtain more efficient and expandable service to extend chemical coverage.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2021
- Accession Number
- AD1130827
Entities
People
- Dean P. Jones
Organizations
- Emory University